πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

5,027 results for β€œERA” Clear

  1. Loncastuximab tesirine

    ADC Therapeutics SA

    Diffuse Large B-Cell Lymphoma Refractory

    phase 2 small molecule completed

    1 trial

  2. Loncastuximab tesirine 150 Β΅g/Kg

    ADC Therapeutics SA

    Marginal Zone Lymphoma

    phase 2 small molecule active

    1 trial

  3. Lorundrostat

    Mineralys Therapeutics

    Obstructive Sleep Apnea

    phase 2 small molecule completed

    1 trial

  4. Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD

    Mineralys Therapeutics

    Chronic Kidney Disease

    phase 2 small molecule completed

    1 trial

  5. Lorviqua 100 mg film-coated tablets, Lorviqua 25 mg film-coated tablets

    CERO THERAPEUTICS HOLDINGS, INC.

    Advanced ROS1-positive non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  6. Losartan

    United Therapeutics Europe Ltd

    Hip Osteoarthritis

    phase 2 small molecule terminated

    1 trial

  7. Losmapimod

    Fulcrum Therapeutics

    Facioscapulohumeral Muscular Dystrophy 1

    phase 2 small molecule terminated

    1 trial

  8. Losmapimod

    United Therapeutics Europe Ltd

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule completed

    1 trial

  9. Losmapimod

    Fulcrum Therapeutics

    Facioscapulohumeral Muscular Dystrophy 1 (FSHD1)

    phase 2 small molecule active

    1 trial

  10. Losmapimod

    Fulcrum Therapeutics

    Facioscapulohumeral Muscular Dystrophy 1 (FSHD1)

    phase 2 small molecule active

    1 trial

  11. Losmapimod oral tablet

    Fulcrum Therapeutics

    Facioscapulohumeral Muscular Dystrophy (FSHD)

    phase 2 small molecule completed

    1 trial

  12. Lovaza, omega-3 fatty acid ethyl ester

    United Therapeutics Europe Ltd

    Mood Disorders

    phase 2 small molecule active

    1 trial

  13. Low Dose ARD-501

    Ark Therapeutics

    Autism Spectrum Disorder

    phase 2 small molecule completed

    1 trial

  14. Low Dose GC4419: 30mg/day

    Galera Therapeutics

    Radiation Induced Oral Mucositis

    phase 2 small molecule completed

    1 trial

  15. Low Dose GT-02287

    Gain Therapeutics

    Parkinson Disease

    phase 2 small molecule active

    1 trial

  16. Low Dose SKY0402

    Pacira Ireland Limited

    Postoperative Pain

    phase 2 small molecule terminated

    1 trial

  17. Low dose FRΞ± vaccine

    Marker Therapeutics

    Breast Cancer

    phase 2 mab completed

    1 trial

  18. Low dose LX2006

    Lexeo Therapeutics

    Friedreich Ataxia

    phase 2 gene therapy active

    1 trial

  19. Low-dose ASA

    Atrium Therapeutics

    Germ Cell Tumor

    phase 2 small molecule active

    1 trial

  20. Lucinactant

    WINDTREE THERAPEUTICS INC /DE/

    COVID-19

    phase 2 small molecule completed

    1 trial

  21. Lucinactant

    WINDTREE THERAPEUTICS INC /DE/

    Acute Hypoxemic Respiratory Failure

    phase 2 small molecule completed

    1 trial

  22. Lucinactant 175 mg/kg

    WINDTREE THERAPEUTICS INC /DE/

    Respiratory Distress Syndrome, Newborn

    phase 2 small molecule terminated

    1 trial

  23. Lucinactant delivered via investigational delivery device

    WINDTREE THERAPEUTICS INC /DE/

    Respiratory Distress Syndrome

    phase 2 small molecule completed

    1 trial

  24. Lucinactant first

    WINDTREE THERAPEUTICS INC /DE/

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources